LyGenesis, Inc., a biotechnology company focused on organ regeneration, announced the closing of US$4 million in private financing of convertible notes from BVI-registered holding company Juvenescence, Ltd. and Longevity Vision Fund. This convertible debt financing will allow LyGenesis to start transition of liver regeneration program into clinical development stage.
Greg Bailey, MD, Co-Founder and CEO of Juvenescence and a member of LyGenesis’s Board of Directors, said in his comments: “We are thrilled to continue our financial support of LyGenesis as they transition into clinical development.” Sergey Young, founder of Longevity Vision Fund, said “The progress of LyGenesis’s technology is emblematic of the rapid advances we are witnessing as biotechnology transitions from bench research, to preclinical models, and now into the clinic.”
